FET family proto-oncogene Fus contributes to self-renewal of hematopoietic stem cells

Experimental Hematology

Volumn 38, Issue 8, 2010, Pages 696-706

  Sugawara, Takeaki ^a,b   Oguro, Hideyuki ^a   Negishi, Masamitsu ^a   Morita, Yohei ^c   Ichikawa, Hitoshi ^d   Iseki, Toru ^a,b   Yokosuka, Osamu ^a   Nakauchi, Hiromitsu ^c,e   Iwama, Atsushi ^a,e  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c THE UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; COCULTURE; COLONY FORMING CELL; CONTROLLED STUDY; DNA DAMAGE; FETUS; FETUS LIVER; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTO ONCOGENE; RADIOSENSITIVITY; RECIPIENT; STROMA CELL;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; FETUS; GAMMA RAYS; HEMATOPOIETIC STEM CELLS; HUMANS; LIVER; MICE; MICE, KNOCKOUT; RADIATION TOLERANCE; RNA-BINDING PROTEIN FUS;

MUS;

EID: 77954485095     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.04.006     Document Type: Article

References (48)

1. Crozat A., Aman P., Mandahl N., et al. Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993, 363:640-644.
2. Rabbitts T.H., Forster A., Larson R., et al. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t (12;16) in malignant liposarcoma. Nat Genet 1993, 4:175-180.
3. Shimizu K., Ichikawa H., Tojo A., et al. An ETS-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc Natl Acad Sci U S A 1993, 90:10280-10284.
4. Ichikawa H., Shimizu K., Hayashi Y., et al. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 1994, 54:2865-2868.
5. Kong X.T., Ida K., Ichikawa H., et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood 1997, 90:1192-1199.
6. Pérez-Losada J., Pintado B., Gutiérrez-Adán A., et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 2000, 19:2413-2422.
7. Riggi N., Cironi L., Provero P., et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006, 66:7016-7023.
8. Ichikawa H., Shimizu K., Katsu R., et al. Dual transforming activities of the FUS (TLS)-ERG leukemia fusion protein conferred by two N-terminal domains of FUS (TLS). Mol Cell Biol 1999, 19:7639-7650.
9. Pereira D.S., Dorrell C., Ito C.Y., et al. Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells. Proc Natl Acad Sci U S A 1998, 95:8239-8244.
10. Warner J.K., Wang J.C., Takenaka K., et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 2005, 19:1794-1805.
11. Bertolotti A., Lutz Y., Heard D.J., et al. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J 1996, 15:5022-5031.
12. Prasad D.D.K., Ouchida M., Lee L., et al. TLS/FUS fusion domain of TLS/FUS-ERG chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene 1994, 9:3717-3729.
13. Zinszner H., Albalat R., Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 1994, 8:2513-2526.
14. May W.A., Lessnick S.L., Braun B.S., et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993, 13:7393-7398.
15. Bertolotti A., Bell B., Tora L. The N-terminal domain of human TAFII68 displays transactivation and oncogenic properties. Oncogene 1999, 18:8000-8010.
16. Lerga A., Hallier M., Delva L., et al. Identification of an RNA binding specificity for the potential splicing factor TLS. J Biol Chem 2001, 276:6807-6816.
17. Yang L., Embree L.J., Tsai S., et al. Oncoprotein TLS interacts with serine-arginine proteins involved in RNA splicing. J Biol Chem 1998, 273:27761-27764.
18. Yang L., Embree L.J., Hickstein D.D. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol Cell Biol 2000, 20:3345-3354.
19. Yang L., Chansky H.A., Hickstein D.D. EWS/Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem 2000, 275:37612-37618.
20. Chansky H.A., Hu M., Hickstein D.D., et al. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res 2001, 61:3586-3590.
21. Hicks G.G., Singh N., Nashabi A., et al. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 2000, 24:175-179.
22. -/- mice. EMBO J 2000, 19:453-462.
23. Okuda T., van Deursen J., Hiebert S.W., et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996, 84:321-330.
24. McMahon K.A., Hiew S.Y., Hadjur S., et al. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 2007, 1:338-345.
25. Jude C.D., Climer L., Xu D., et al. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 2007, 1:324-337.
26. Goyama S., Yamamoto G., Shimabe M., et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008, 3:207-220.
27. Loughran S.J., Kruse E.A., Hacking D.F., et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol 2008, 9:810-819.
28. Aman P., Panagopoulos I., Lassen C., et al. Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics 1996, 37:1-8.
29. Kim I., He S., Yilmaz H.Ö., Kiel M.J., et al. Enhanced purification of fetal liver hematopoietic stem cells using SLAM family receptors. Blood 2006, 108:737-744.
30. NijNik A., Woodbine L., Marchetti C., et al. DNA repair is limiting for haematopoietic stem cells during ageing. Nature 2007, 447:686-691.
31. Rossi D.J., Bryder D., Seita J., et al. Deficiencies in DNA damage repair limit the function of haematopoietic stem cell with age. Nature 2007, 447:725-730.
32. Rogakou E.P., Pilch D.R., Orr A.H., et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868.
33. Allsopp R.C., Morin G.B., DePinho R., et al. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 2003, 102:517-520.
34. Choudhury A.R., Ju Z., Djojosubroto M.W., et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet 2007, 39:99-105.
35. Miyamoto K., Araki K.Y., Naka K., et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007, 1:101-112.
36. Takahashi A., Higashio F., Aoyagi M., et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003, 63:8338-8344.
37. Bertrand P., Akhmedov A.T., Delacote F., et al. Human POMp75 is identified as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation. Oncogene 1999, 18:4515-4521.
38. Baechtold H., Kuroda M., Sok J., et al. Human 75-kDa DNA-pairing protein is identical to the pro-oncoprotein TLS/FUS and is able to promote D-loop formation. J Biol Chem 1999, 274:34337-34342.
39. Gardiner M., Toth R., Vandermoere F., et al. Identification and characterization of FUS/TLS as a new target of ATM. Biochem J 2008, 415:297-307.
40. Zhou B.B.S., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
41. Wang X., Arai S., Song X., et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 2008, 454:126-130.
42. Fujii R., Takumi T. TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J Cell Sci 2005, 118:5755-5765.
43. Kwiaatkowski T.J., Bosco D.A., LeClerc A.L., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
44. Vance C., Rogelj B., Hortobagyi T., et al. Mutations in the FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1205-1211.
45. Li H., Watford W., Li C., et al. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J Clin Invest 2007, 117:1314-1323.
46. Mills K.I., Walsh V., Gilkes A.F., et al. High TLS/FUS expression in acute myeloid leukemia samples. Br J Haematol 2000, 108:316-321.
47. Perrotti D., Bonatti S., Trotta R., et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J 1998, 17:4442-4455.
48. Perroti D., Iervolino A., Cesi V., et al. BCR-ABL prevents c-Jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CβII-dependent pathway. Mol Cell Biol 2000, 20:6159-6169.